{"id":"https://openalex.org/W7225812315","doi":"https://doi.org/10.3389/fimmu.2026.1986549","title":"Local PD-1/PD-L1 RNAi to complement immune checkpoint blockade: the dual-hit hypothesis in cutaneous malignancies","display_name":"Local PD-1/PD-L1 RNAi to complement immune checkpoint blockade: the dual-hit hypothesis in cutaneous malignancies","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7225812315","doi":"https://doi.org/10.3389/fimmu.2026.1986549"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.1986549","doi":"https://doi.org/10.3389/fimmu.2026.1986549","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1986549","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1986549/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1986549/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161440421","display_name":"Xiaoxia Ye","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoxia Ye","raw_affiliation_strings":["Department of Dermatology, Ganzhou Dermatosis Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Ganzhou Dermatosis Hospital","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039250111","display_name":"Yi Lan","orcid":"https://orcid.org/0000-0002-6801-0155","observed_orcids":["https://orcid.org/0000-0002-6801-0155"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yi Lan","raw_affiliation_strings":["Department of Pharmaceutical and Medical Devices, Ganzhou Dermatosis Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical and Medical Devices, Ganzhou Dermatosis Hospital","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161473794","display_name":"Wenlong Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Wenlong Zhou","raw_affiliation_strings":["Department of Medical Affairs, Guangzhou Xinhui Biotechnology Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Affairs, Guangzhou Xinhui Biotechnology Co., Ltd","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5161473794"],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.6679999828338623},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.6272000074386597},{"id":"https://openalex.org/C119056186","wikidata":"https://www.wikidata.org/wiki/Q1431332","display_name":"Gene silencing","level":3,"score":0.6229000091552734},{"id":"https://openalex.org/C166703698","wikidata":"https://www.wikidata.org/wiki/Q201993","display_name":"RNA interference","level":4,"score":0.608299970626831},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5529999732971191},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5485000014305115},{"id":"https://openalex.org/C22615655","wikidata":"https://www.wikidata.org/wiki/Q203221","display_name":"Small interfering RNA","level":4,"score":0.5318999886512756},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5006999969482422},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.40139999985694885},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.3828999996185303},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3736000061035156},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3725000023841858},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35690000653266907},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.34060001373291016},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3345000147819519},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3328999876976013},{"id":"https://openalex.org/C179185449","wikidata":"https://www.wikidata.org/wiki/Q219699","display_name":"Suppressor","level":3,"score":0.31299999356269836},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.30300000309944153},{"id":"https://openalex.org/C45121317","wikidata":"https://www.wikidata.org/wiki/Q4927287","display_name":"Blocking antibody","level":3,"score":0.27469998598098755},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.2711000144481659},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.25769999623298645},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.2572999894618988},{"id":"https://openalex.org/C144745244","wikidata":"https://www.wikidata.org/wiki/Q4927286","display_name":"Blocking (statistics)","level":2,"score":0.2540999948978424},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.25119999051094055}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3389/fimmu.2026.1986549","doi":"https://doi.org/10.3389/fimmu.2026.1986549","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1986549","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1986549/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.1986549","doi":"https://doi.org/10.3389/fimmu.2026.1986549","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1986549","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1986549/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225812315.pdf","grobid_xml":"https://content.openalex.org/works/W7225812315.grobid-xml"},"referenced_works_count":75,"referenced_works":["https://openalex.org/W1647075334","https://openalex.org/W1966820518","https://openalex.org/W1967389270","https://openalex.org/W1971643509","https://openalex.org/W1980002305","https://openalex.org/W1983605860","https://openalex.org/W2007528556","https://openalex.org/W2020469175","https://openalex.org/W2027954222","https://openalex.org/W2046981853","https://openalex.org/W2055384999","https://openalex.org/W2057755828","https://openalex.org/W2071596792","https://openalex.org/W2101543035","https://openalex.org/W2103802203","https://openalex.org/W2128035403","https://openalex.org/W2155239981","https://openalex.org/W2165586566","https://openalex.org/W2745683917","https://openalex.org/W2802881274","https://openalex.org/W2805968856","https://openalex.org/W2897984395","https://openalex.org/W2901621951","https://openalex.org/W2925446385","https://openalex.org/W3018388059","https://openalex.org/W3030448313","https://openalex.org/W3036363721","https://openalex.org/W3154020616","https://openalex.org/W3154805493","https://openalex.org/W3205955629","https://openalex.org/W3212402614","https://openalex.org/W4214816481","https://openalex.org/W4229449699","https://openalex.org/W4283365834","https://openalex.org/W4304187182","https://openalex.org/W4313889865","https://openalex.org/W4385220785","https://openalex.org/W4385698085","https://openalex.org/W4389801657","https://openalex.org/W4391843620","https://openalex.org/W4395465789","https://openalex.org/W4399359178","https://openalex.org/W4402245614","https://openalex.org/W4402266106","https://openalex.org/W4403108780","https://openalex.org/W4403271053","https://openalex.org/W4404723298","https://openalex.org/W4405020609","https://openalex.org/W4405187423","https://openalex.org/W4405566880","https://openalex.org/W4406043782","https://openalex.org/W4406117310","https://openalex.org/W4406445815","https://openalex.org/W4406998503","https://openalex.org/W4407998297","https://openalex.org/W4408509097","https://openalex.org/W4408841186","https://openalex.org/W4409481794","https://openalex.org/W4409717143","https://openalex.org/W4411910369","https://openalex.org/W4412488244","https://openalex.org/W4412516112","https://openalex.org/W4414138035","https://openalex.org/W4415424776","https://openalex.org/W4416088141","https://openalex.org/W4416417213","https://openalex.org/W4416976927","https://openalex.org/W4417416261","https://openalex.org/W4417506867","https://openalex.org/W7033783247","https://openalex.org/W7133497896","https://openalex.org/W7161026195","https://openalex.org/W7162325825","https://openalex.org/W7201881712","https://openalex.org/W7213443844"],"related_works":[],"abstract_inverted_index":{"Programmed":[0],"cell":[1],"death":[2],"protein":[3],"1/programmed":[4],"death-ligand":[5],"1":[6],"(PD-1/PD-L1)":[7],"immune":[8,85],"checkpoint":[9,92],"inhibitors":[10],"(ICIs)":[11],"have":[12,32],"substantially":[13],"improved":[14],"outcomes":[15],"in":[16,78],"advanced":[17],"skin":[18],"malignancies.":[19],"However,":[20],"many":[21],"patients":[22,158],"still":[23],"show":[24],"resistance,":[25],"experience":[26],"immune-related":[27],"adverse":[28],"events":[29],"(irAEs),":[30],"or":[31,156],"uneven":[33],"antibody":[34],"penetration":[35],"into":[36],"tumors.":[37],"Small":[38],"interfering":[39],"RNAs":[40],"(siRNAs)":[41],"provide":[42],"an":[43],"alternative":[44],"means":[45],"of":[46,58,127],"targeting":[47],"the":[48,64,83,95,104,115,124,132],"same":[49],"pathway":[50],"by":[51],"promoting":[52],"RNA-induced":[53],"silencing":[54],"complex":[55],"(RISC)-mediated":[56],"degradation":[57],"PD-1/PD-L1":[59,76],"transcripts":[60],"rather":[61],"than":[62],"blocking":[63],"corresponding":[65],"proteins":[66],"with":[67,159],"antibodies.":[68],"We":[69,98],"propose":[70],"that":[71,138],"intratumoral":[72],"siRNA":[73],"could":[74,90],"reduce":[75],"expression":[77],"treated":[79],"tumors":[80],"and":[81,113,119,135,164],"alter":[82,153],"local":[84],"microenvironment,":[86],"while":[87],"systemic":[88],"ICI":[89,151],"extend":[91],"blockade":[93],"beyond":[94],"injected":[96],"lesion.":[97],"refer":[99],"to":[100],"this":[101,144],"strategy":[102],"as":[103],"Dual-Hit":[105],"hypothesis.":[106],"This":[107],"article":[108],"examines":[109],"its":[110],"mechanistic":[111],"basis":[112],"summarizes":[114],"available":[116],"preclinical":[117],"evidence":[118],"early":[120],"clinical":[121,141,166],"experience,":[122],"including":[123],"first-in-human":[125],"study":[126],"PH-762.":[128],"It":[129],"also":[130],"considers":[131],"delivery,":[133],"intracellular,":[134],"safety-related":[136],"factors":[137],"may":[139],"affect":[140],"development.":[142],"Whether":[143],"combination":[145],"can":[146],"improve":[147],"antitumor":[148],"activity":[149],"over":[150],"alone,":[152],"treatment":[154],"requirements,":[155],"benefit":[157],"ICI-refractory":[160],"disease":[161],"remains":[162],"unknown":[163],"requires":[165],"testing.":[167]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-12T00:00:00"}